IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-31401-5.html
   My bibliography  Save this article

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines

Author

Listed:
  • Stéphane Vu

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Marion Bertrand

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Marie-Joelle Jabagi

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Jérémie Botton

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
    Université Paris-Saclay)

  • Jérôme Drouin

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Bérangère Baricault

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Alain Weill

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Rosemary Dray-Spira

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM))

  • Mahmoud Zureik

    ((French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM)
    University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology)

Abstract

Cases of myocarditis and pericarditis have been reported following the receipt of Covid-19 mRNA vaccines. As vaccination campaigns are still to be extended, we aimed to provide a comprehensive assessment of the association, by vaccine and across sex and age groups. Using nationwide hospital discharge and vaccine data, we analysed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 and 30 (95% CI, 21 to 43) for the mRNA-1273 vaccine. The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.

Suggested Citation

  • Stéphane Vu & Marion Bertrand & Marie-Joelle Jabagi & Jérémie Botton & Jérôme Drouin & Bérangère Baricault & Alain Weill & Rosemary Dray-Spira & Mahmoud Zureik, 2022. "Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31401-5
    DOI: 10.1038/s41467-022-31401-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-31401-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-31401-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marco A. F. Pimentel & Maaz Shaikh & Muna Al Safi & Yousuf Naqvi & Shadab Khan, 2024. "COVID-19 vaccination and major cardiovascular and haematological adverse events in Abu Dhabi: retrospective cohort study," Nature Communications, Nature, vol. 15(1), pages 1-8, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31401-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.